NASDAQ$ANTX
AN2 Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
AN2 Therapeutics reported Q2 2024, net loss of $14.4M.
For Q2 2024, AN2 Therapeutics reported a net loss of $14.4M. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $14.4M.
- AN2 Therapeutics MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
AN2 Therapeutics · Revenue · Quarterly
$0
Forward guidance
Pre-revenue or early-stage biotech emphasizes pipeline milestones and cash runway.
Tailwinds
- Clinical progress and partnerships.
- Regulatory pathway optionality.
- Balance-sheet flexibility.
Headwinds
- Operating losses and financing needs.
- Trial and regulatory risk.
- Commercialization timing uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2024
+8.9%
Avg return
Earnings day
+14.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
47%
9 / 19 earnings
Positive
+75.2%
Q2 2021
Best reaction
-6.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.9% | +0.8% | -5.7% | |
| Q3 2025 | -4.3% | -5.1% | +1.7% | |
| Q2 2024 | +1.9% | +6.2% | +21.3% | |
| Q2 2025 | +0.0% | +6.2% | +21.3% | |
| Q1 2025 | -1.7% | -1.7% | -10.7% | |
| Q4 2024 | -2.4% | -9.3% | -16.7% | |
| Q3 2024 | -5.7% | -5.7% | +34.9% | |
| Q1 2024 | -3.4% | -3.4% | -15.3% | |
| Q4 2023 | +16.8% | +5.6% | -28.0% | |
| Q3 2023 | -6.2% | +4.5% | +23.2% | |
| Q2 2023 | +2.8% | +5.4% | +90.1% | |
| Q1 2023 | +0.4% | +46.2% | +48.5% | |
| Q4 2022 | +1.8% | +4.8% | -17.0% | |
| Q3 2021 | -3.5% | -3.3% | -41.4% | |
| Q3 2022 | -3.5% | -3.3% | -41.4% | |
| Q2 2022 | +75.2% | +95.8% | -14.6% | |
| Q2 2021 | +75.2% | +95.8% | -14.6% | |
| Q4 2021 | +14.2% | +16.9% | -32.9% | |
| Q1 2022 | +14.2% | +16.9% | -32.9% | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro